CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Apexigen Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Apexigen Inc
900 Industrial Road, Suite C
Phone: (650) 931-6236p:650 931-6236 San Carlos, CA  94070  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 8/23/2023.
This company ceased filing statements with the SEC on 9/5/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Apexigen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient’s immune system to combat and eradicate cancer. It has developed a clinical-stage candidate, namely sotigalimab (sotiga or APX005M), which is a humanized agonist antibody. It also has various preclinical and research-stage antibodies it discovered using its APXiMAB platform. It is focused on completing ongoing clinical and manufacturing activities for the sotiga program. The Company’s licensees are advancing five product candidates in clinical development that were enabled by discoveries from its APXiMAB platform. APX005M is under Phase II clinical development for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction cancers and melanoma, in combination with chemotherapy, radiation therapy and immunotherapy.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYes--Yes

Industries
SIC Code Description
6770 Blank checks
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board MeenuKarson 7/1/2022 7/1/2022
President, Chief Operating Officer Francis W.Sarena 2/1/2023 7/1/2022
Chief Executive Officer, Director XiaodongYang 7/1/2022 7/1/2022
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 12 (As of 3/31/2023)
Outstanding Shares: 31,680,306 (As of 8/22/2023)
Shareholders: 8
Stock Exchange: NASD
Federal Tax Id: 851260244
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024